Welcome to our dedicated page for Zevra Therapeutics news (Ticker: ZVRA), a resource for investors and traders seeking the latest updates and insights on Zevra Therapeutics stock.
Zevra Therapeutics, Inc. (symbol: ZVRA) is a pioneering rare disease company dedicated to developing transformational therapies for conditions with limited or no treatment options. By combining science, data, and patient needs, Zevra aims to deliver life-changing solutions to individuals living with rare diseases. Their mission is to address these unmet medical needs through unique, data-driven development and commercialization strategies.
Zevra Therapeutics utilizes its proprietary Ligand Activated Therapy (LAT) approach to create improved prodrug versions of FDA-approved medications. These prodrugs target high-need areas such as pain management, ADHD, and other central nervous system diseases. Through this innovative technology, Zevra is overcoming complex drug development challenges and making new therapies accessible to the rare disease community.
Recent achievements include significant advancements in their pipeline projects, particularly in pain and ADHD treatment. The company is also known for its strategic partnerships, which enhance its research and development capabilities and accelerate the commercialization of its therapies. Financially, Zevra has a solid foundation, allowing it to focus on its core mission of addressing rare diseases and improving patients' lives.
For up-to-date information, news, and latest developments, Zevra encourages stakeholders to stay connected through their official contact points:
- Nichol Ochsner: +1 (732) 754-2545, nochsner@zevra.com
- Russo Partners: David Schull: +1 (858) 717-2310, david.schull@russopartnersllc.com
- Russo Partners: Ignacio Guerrero-Ros, Ph.D.: +1 (646) 942-5604, ignacio.guerrero-ros@russopartnersllc.com
Rhea-AI Summary
Zevra Therapeutics, Inc. announces FDA extension of arimoclomol NDA review for Niemann-Pick disease type C with a new PDUFA action date of September 21, 2024. The company remains optimistic about the potential of arimoclomol to help patients despite the delay.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.15%
Tags
-
Rhea-AI Summary
Zevra Therapeutics, Inc. (ZVRA) announces Neil F. McFarlane, President and CEO, will present at investor conferences in March 2024. The company will participate in TD Cowen 44th Annual Health Care Conference and 36th Annual ROTH Conference. The live webcasts will be available on Zevra's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
-
News
Rhea-AI Summary
Zevra Therapeutics, Inc. (ZVRA) will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024. The company's management team will also be available for one-on-one investor meetings. The live webcast will be accessible on the company's website, and the archived presentation will be available thereafter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.34%
Tags
Rhea-AI Summary
Zevra Therapeutics, Inc. appoints Alvin Shih, MD, MBA, to its Board of Directors. Dr. Shih brings extensive experience in biotechnology leadership and rare disease therapeutics development. He has held leadership roles at various biotechnology companies and has a strong background in drug development for rare diseases. Zevra's Board and management team express confidence in Dr. Shih's ability to contribute to the advancement of the company's therapeutic portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.5%
Tags
-
Rhea-AI Summary
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) has announced that the U.S. FDA has assigned a PDUFA action date of June 21, 2024, for the resubmission of the New Drug Application (NDA) for arimoclomol as a first-in-class treatment for Niemann-Pick disease type C. The resubmission addresses concerns previously raised in the FDA's complete response letter and includes additional evidence supporting trial metrics and data from multiple additional studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.9%
Tags
-
Rhea-AI Summary
Zevra Therapeutics, Inc. (ZVRA) appoints Dr. Adrian Quartel, M.D., FFPM, as Chief Medical Officer, bringing extensive experience in the pharmaceutical industry. Dr. Quartel's appointment follows Zevra's recent acquisition of Acer Therapeutics, expanding their rare disease portfolio. The company aims to develop and commercialize therapies for rare and ultra-rare diseases with significant unmet needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.21%
Tags
Rhea-AI Summary
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) resubmits NDA for arimoclomol, an investigational therapeutic candidate for Niemann-Pick disease type C (NPC) to the FDA. The NDA is expected to be classified as a Class II submission, subject to a review period within six months. The resubmission includes additional evidence, new data, and results from multiple non-clinical studies and early access programs, suggesting arimoclomol's potential to reduce the progression of NPC. Arimoclomol has been evaluated in 21 studies across Phase 1, 2, and 3 trials, showing promise in treating NPC and other diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.71%
Tags
-
Rhea-AI Summary
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) completes acquisition of Acer Therapeutics Inc., propelling the company into the commercial stage with OLPRUVA®, an FDA-approved treatment for urea cycle disorders (UCDs). The settlement of Acer’s warrant obligations diversifies Zevra's revenue and adds a quality healthcare investor to its shareholder base. The acquisition includes 2.96 million shares of Zevra stock and contingent value rights (CVRs) worth up to $76 million. Zevra also purchased Acer’s senior secured debt for $28.5 million, further strengthening its position in developing and commercializing treatments for rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.23%
Tags
-
Rhea-AI Summary
Zevra Therapeutics, Inc. reported net revenue of $2.9M for Q3 2023 and ended the quarter with $83.4M in cash. The company is on track to resubmit the arimoclomol NDA by the end of the year. The proposed acquisition of Acer Therapeutics is expected to close in Q4 2023, diversifying Zevra's revenue with FDA-approved OLPRUVA® for urea cycle disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.51%
Tags
Rhea-AI Summary
Zevra Therapeutics, Inc. will host a conference call and live audio webcast on November 7, 2023, to review its corporate and financial results for Q3 2023. The webcast will be accessible via the Investor Relations section of the company's website. The conference call dial-in information is provided. An archive of the webcast will be available for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.46%
Tags
FAQ
What is the current stock price of Zevra Therapeutics (ZVRA)?
The current stock price of Zevra Therapeutics (ZVRA) is $7.33 as of March 3, 2025.
What is the market cap of Zevra Therapeutics (ZVRA)?
The market cap of Zevra Therapeutics (ZVRA) is approximately 420.1M.
What does Zevra Therapeutics, Inc. specialize in?
Zevra Therapeutics focuses on developing transformational therapies for rare diseases using their proprietary LAT technology.
What is the company's mission?
The mission of Zevra Therapeutics is to bring life-changing therapeutics to people living with rare diseases.
What is the Ligand Activated Therapy (LAT) approach?
The LAT approach is a proprietary method used by Zevra to create improved prodrug versions of FDA-approved medications.
Which areas of medical needs does Zevra's technology target?
Zevra's technology targets high-need areas such as pain management, ADHD, and other central nervous system diseases.
Who are the primary contacts for investor relations?
Primary contacts include Nichol Ochsner, David Schull, and Ignacio Guerrero-Ros, Ph.D.
How does Zevra ensure the financial stability of their projects?
Zevra has a solid financial foundation, allowing them to focus on their core mission of addressing rare diseases.
What recent achievements has Zevra made?
Zevra has made significant advancements in their pipeline projects, especially in pain and ADHD treatment.
What kind of partnerships does Zevra engage in?
Zevra engages in strategic partnerships to enhance research, development, and accelerate commercialization efforts.
How can stakeholders stay updated with Zevra's latest news?
Stakeholders can stay updated by connecting with official contact points including Nichol Ochsner and representatives from Russo Partners.
What is the significance of Zevra’s prodrug development?
Zevra's prodrug development is significant as it creates improved versions of existing FDA-approved drugs to better meet patient needs.
Zevra Therapeutics Inc
Nasdaq:ZVRA
ZVRA Rankings
ZVRA Stock Data
420.07M
49.06M
6.56%
54.37%
10.25%
Biotechnology
Pharmaceutical Preparations
United States
CELEBRATION